Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company PIC

Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked

Fineline Cube Aug 27, 2026
Company PIC

HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43%

Fineline Cube Aug 27, 2026
Company PIC

Junshi Biosciences Achieves First‑Ever Semiannual Profitability as Toripalimab Sales Surge 36%

Fineline Cube Aug 27, 2026
Company Drug PIC

FDA Approves Revolution Medicines’ Rasonque (daraxonrasib), an Oral Multi‑Selective RAS(ON) Inhibitor, for Metastatic Pancreatic Cancer

Fineline Cube Aug 27, 2026
Company Drug PIC

NMPA Approves Novartis’ Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer

Fineline Cube Aug 26, 2026
Company PIC

Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked

Fineline Cube Aug 27, 2026
Company PIC

Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked

Fineline Cube Aug 27, 2026
Company PIC

HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43%

Fineline Cube Aug 27, 2026
Policy / Regulatory

Hubei Province Proposes National TCM Patent Medicine Procurement Alliance

Fineline Cube Sep 15, 2022

The Healthcare Security Administration of Hubei Province has proposed the establishment of a national traditional...

Company Drug

Buchang Pharmaceuticals Gains NMPA Approval for BC008-1A Clinical Study

Fineline Cube Sep 15, 2022

China-based Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858) announced that it has received approval from...

Company Drug

CDE Prioritizes Review of Pearl Bio’s Breatinib for NSCLC Treatment

Fineline Cube Sep 15, 2022

The Center for Drug Evaluation (CDE) website indicates that Beijing Pearl Biotechnology Co., Ltd’s APL-101/PLB1001...

Company Drug

Jiangsu Hengrui Medicine Gains NMPA Approval for HRS-6209 Clinical Study

Fineline Cube Sep 15, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received approval from...

Company Drug

I-Mab’s Lemzoparlimab Gains CDE Approval for HR-MDS Phase III Trial

Fineline Cube Sep 14, 2022

China-based I-Mab (NASDAQ: IMAB) announced that it has successfully completed an End-of-Phase 2 (EoP2) meeting...

Company Drug

Takeda’s Modakafusp Alfa and TAK-981 Gain NMPA Clinical Trial Approvals

Fineline Cube Sep 14, 2022

The National Medical Products Administration (NMPA) website indicates that Japan-based Takeda Pharmaceutical Co., Ltd’s (TYO:...

Company Drug

Huahai Pharmaceutical Gains FDA Approval for Generic Fingolimod

Fineline Cube Sep 14, 2022

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received Abbreviated New...

Company Deals

Vathin Medical Instrument Raises Pre-Series B Funding Led by IDG Capital

Fineline Cube Sep 14, 2022

China-based single-use bronchoscope specialist Hunan Vathin Medical Instrument Co., Ltd reportedly raised “hundreds of millions”...

Company Policy / Regulatory

NMPA Issues Guidelines on Medical Device Grading Administration

Fineline Cube Sep 14, 2022

The National Medical Products Administration (NMPA) has released a set of Guiding Opinions on “Medical...

Policy / Regulatory

Frontier Biotech’s FB2001 Inhalant Accepted for NMPA Review

Fineline Cube Sep 14, 2022

China-based Frontier Biotechnologies Inc. (SHA: 688221) announced that a registrational clinical filing for its FB2001...

Company Drug

Luye Pharma’s LY03015 Receives FDA Approval for Phase I Clinical Study

Fineline Cube Sep 14, 2022

China-based Luye Pharma Group (HKG: 2186) announced that it has received approval from the US...

Company Deals

Hengrui Medicine to Incentivize Employees with Share Distribution

Fineline Cube Sep 14, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced plans to incentivize its employees...

Policy / Regulatory

Biden’s Executive Order Boosts US Bio-Economy, Targets China’s Biotech Rise

Fineline Cube Sep 13, 2022

US President Joe Biden signed an executive order on Monday, outlining steps to bolster the...

Company Deals

QuantuMDx and Sansure Biotech Partner to Commercialize Q-POC in China

Fineline Cube Sep 13, 2022

UK-based QuantuMDx Group Ltd announced a global R&D, manufacturing, and commercial partnership with China’s Sansure...

Company Drug

InnoCare Pharma’s BCL2 Inhibitor ICP-248 Gains NMPA Approval for Clinical Study

Fineline Cube Sep 13, 2022

China’s Beijing InnoCare Pharma (HKG: 9969) announced that it has received approval from the National...

Company Drug

BeiGene’s Tislelizumab Meets Primary Endpoint in HCC Study at ESMO

Fineline Cube Sep 13, 2022

BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) presented the latest results of the global Phase...

Company Drug

Luye Pharma’s BA-CovMab Receives NMPA Approval for COVID-19 Clinical Trials

Fineline Cube Sep 13, 2022

China-based Luye Pharma Group (HKG: 2186) announced that its subsidiary Shandong BoAn Biotechnology Co., Ltd’s...

Policy / Regulatory

Jiangsu Healthcare to Cover All Psychological Treatments Under BMI

Fineline Cube Sep 13, 2022

The Jiangsu Provincial Healthcare Security Administration is reportedly considering adding all psychological diagnosis and treatment...

Company Deals

Leadinno Medical Valley Raises RMB 100M in Series A Financing for Neuromodulation Devices

Fineline Cube Sep 13, 2022

Beijing-based neuromodulation medical device maker Leadinno Medical Valley reportedly raised over RMB 100 million (USD...

Company Drug

Transcenta’s TST001 Shows Promise in Gastric Cancer Trial with 73.3% Response Rate

Fineline Cube Sep 13, 2022

China-based biotech Transcenta Holdings Ltd (HKG: 6628) announced interim safety and efficacy data from a...

Posts pagination

1 … 672 673 674 … 713

Recent updates

  • Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked
  • HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43%
  • CSPC’s PD-1/IL-15 Bispecific SYS6090 (JMT108) Granted FDA Fast Track for MSS/pMMR Metastatic Colorectal Cancer
  • Insilico Medicine Swings to Profitability as Revenue Surges 287% in 1H 2026, Rentosertib Advances to Phase 3
  • Huadong Medicine’s ROR1 ADC HDM2005 Granted FDA Fast Track Designation — First Domestic ROR1 ADC to Achieve the Status
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company PIC

Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked

Company PIC

HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43%

Company Drug

CSPC’s PD-1/IL-15 Bispecific SYS6090 (JMT108) Granted FDA Fast Track for MSS/pMMR Metastatic Colorectal Cancer

Company

Insilico Medicine Swings to Profitability as Revenue Surges 287% in 1H 2026, Rentosertib Advances to Phase 3

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.